Abstract
Duchenne muscular dystrophy (DMD) afflicts 1 in 5000 newborn males, leading to progressive muscle weakening and the loss of ambulation between the ages of 8 and 12. Typically, DMD patients pass away from heart failure or respiratory failure. Currently, there is no cure, though exon-skipping therapy including eteplirsen (brand name Exondys 51), a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene, is considered especially promising. Applicable to approximately 14% of DMD patients, a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide eteplirsen received accelerated approval by the US Food and Drug Administration (FDA) in 2016. Throughout clinical trials, eteplirsen has been well tolerated by patients with no serious drug-related adverse events. The most common events observed are balance disorder, vomiting, and skin rash. Despite its safety and promise of functional benefits, eteplirsen remains controversial due to its low production of dystrophin. In addition, unmodified PMOs have limited efficacy in the heart. To address these concerns of efficacy, eteplirsen has been conjugated to a proprietary cell-penetrating peptide; the conjugate is called SRP-5051. Compared to eteplirsen, SRP-5051 aims to better prompt exon-skipping and dystrophin production but may have greater toxicity concerns. This paper reviews and discusses the available information on the efficacy, safety, and tolerability data of eteplirsen and SRP-5051 from preclinical and clinical trials. Issues faced by eteplirsen and SRP-5051, including efficacy and safety, are identified. Lastly, the current state of eteplirsen and exon-skipping therapy in general as a strategy for the treatment of DMD are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Availability of data and material
Not applicable.
Code availability
Not applicable.
References
Aartsma-Rus A, Goemans N (2019) A sequel to the eteplirsen saga: eteplirsen is approved in the united states but was not approved in Europe. Nucl Acid Ther 29(1):13–15. https://doi.org/10.1089/nat.2018.0756
Aartsma-Rus A, Van Deutekom JCT, Fokkema IF, Van Ommen GJB, Den Dunnen JT (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34(2):135–144. https://doi.org/10.1002/mus.20586
Aartsma-Rus A, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, Mercuri E, Muntoni F, Sepodes B, Vroom E, Balabanov P (2017) development of exon skipping therapies for duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucl Acid Ther 27(5):251–259. https://doi.org/10.1089/nat.2017.0682
Alfano LN, Charleston JS, Connolly AM, Cripe L, Donoghue C, Dracker R, Dworzak J, Eliopoulos H, Frank DE, Lewis S, Lucas K, Lynch J, Milici AJ, Flynt A, Naughton E, Rodino-Klapac LR, Sahenk Z, Schnell FJ, Young GD, Lowes LP (2019) Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine 98(26):e15858. https://doi.org/10.1097/md.0000000000015858
Aloysius Z, Pramono D, Takeshima Y, Alimsardjono H, Ishii A, Takeda S, Matsuo M (1996) Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence expression because they offer the exciting possibility of blocking the expressi. Biochem Biophys Res Commun 449:445–449
Alter J, Lou F, Rabinowitz A, Yin HF, Rosenfeld J, Wilton SD, Partridge TA, Qi LL (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12(2):175–177. https://doi.org/10.1038/nm1345
Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomeza V, Armaroli A, Guglieri M, Straathof CS, Verschuuren JJ, Aartsma-Rus A, Helderman-Van Den Enden P, Bushby K, Straub V, Sewry C, Ferlini A, Ricci E, Morgan JE, Muntoni F (2011) Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 134(12):3544–3556. https://doi.org/10.1093/brain/awr291
Anwar S, Yokota T (2020) Golodirsen for Duchenne muscular dystrophy. Drugs Today (barc, Spain: 1998) 56(8):491–504. https://doi.org/10.1358/dot.2020.56.8.3159186
Anwar S, He M, Lim KRQ, Maruyama R, Yokota T (2021) A genotype-phenotype correlation study of exon skip-equivalent in-frame deletions and exon skip-amenable out-of-frame deletions across the DMD gene to simulate the effects of exon-skipping therapies: a meta-analysis. J Pers Med 11(1):46
Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, Takeda S (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18(11):1995–2005. https://doi.org/10.1038/mt.2010.186
Beigel JH, Voell J, Muñoz P, Kumar P, Brooks KM, Zhang J, Iversen P, Heald A, Wong M, Davey RT (2018) Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1 / M2 translation. Br J Clin Pharmacol 84:25–34. https://doi.org/10.1111/bcp.13405
Betts CA, Saleh AF, Carr CA, Hammond SM, Coenen-Stass AML, Godfrey C, McClorey G, Varela MA, Roberts TC, Clarke K, Gait MJ, Wood MJA (2015) Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Sci Rep 5:1–9. https://doi.org/10.1038/srep08986
Beynon RP, Ray SG (2008) Cardiac Involvement in Muscular Dystrophies. QJM 101(5):337–344. https://doi.org/10.1093/qjmed/hcm124
Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Dai Y, Wang J, Barišić N, Brabec P, Lahdetie J, Lochmüller H (2015) The TREAT-NMD DMD global database: Analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36(4):395–402. https://doi.org/10.1002/humu.22758
Blain AM, Greally E, McClorey G, Manzano R, Betts CA, Godfrey C, O’Donovan L, Coursindel T, Gait MJ, Wood MJ, MacGowan GA, Straub VW (2018) Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy. PLoS ONE. https://doi.org/10.1371/journal.pone.0198897
Buddhe S, Cripe L, Friedland-Little J, Kertesz N, Eghtesady P, Finder J, Hor K, Judge DP, Kinnett K, McNally EM, Raman S, Thompson WR, Wagner KR, Olson AK (2018) Cardiac Management of the patient with Duchenne muscular dystrophy. Pediatrics 142:S72–S81. https://doi.org/10.1542/peds.2018-0333L
Carver MP, Charleston JS, Shanks C, Zhang J, Mense M, Sharma AK, Kaur H, Sazani P (2016) Toxicological characterization of exon skipping phosphorodiamidate morpholino oligomers (PMOs) in non-human primates. J Neuromuscul Dis 3:381–393. https://doi.org/10.3233/JND-160157
Charleston JS, Schnell FJ, Dworzak J, Donoghue C, Lewis S, Chen L, David Young G, Milici AJ, Voss J, Dealwis U, Wentworth B, Rodino-Klapac LR, Sahenk Z, Frank D, Mendell JR (2018) Eteplirsen treatment for Duchenne muscular dystrophy. Neurology 90(24):e2135–e2145. https://doi.org/10.1212/WNL.0000000000005680
Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJA, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet (london, England) 378(9791):595–605. https://doi.org/10.1016/S0140-6736(11)60756-3
D’Angelo MG, Berti M, Piccinini L, Romei M, Guglieri M, Bonato S, Degrate A, Carla A, Bresolin N (2009) Gait pattern in Duchenne muscular dystrophy. Gait Posture 29:36–41. https://doi.org/10.1016/j.gaitpost.2008.06.002
de Feraudy Y, Ben Yaou R, Wahbi K, Stalens C, Stantzou A, Laugel V, Desguerre I, Servais L, Leturcq F, Amthor H (2021) Very low residual dystrophin quantity is associated with milder dystrophinopathy. Ann Neurol 89(2):280–292. https://doi.org/10.1002/ana.25951
Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL (2005) In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res 11(10):3930–3938. https://doi.org/10.1158/1078-0432.CCR-04-2091
Dubowitz V (1989) The Duchenne dystrophy story: from phenotype to gene and potential treatment. J Child Neurol 4(4):240–250. https://doi.org/10.1177/088307388900400402
Duchenne D (1867) The Pathology of paralysis with muscular degeneration (paralysie myosclerotique), or paralysis with apparent hypertrophy. Br Med J 2:541–542
Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G (1998) Modification of splicing in the dystrophin gene in cultured mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 5(1):1083–1090
Dzierlega K, Yokota T (2020) Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Gene Ther 27(9):407–416. https://doi.org/10.1038/s41434-020-0156-6
Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T (2017a) Quantitative antisense screening and optimization FOR Exon 51 skipping in Duchenne Muscular dystrophy. Mol Ther 25(11):2561–2572. https://doi.org/10.1016/j.ymthe.2017.07.014
Echigoya Y, Nakamura A, Nagata T, Urasawa N, Lim KRQ, Trieu N, Panesar D, Kuraoka M, Moulton HM, Saito T, Aoki Y, Iversen P, Sazani P, Kole R, Maruyama R, Partridge T, Takeda S, Yokota T (2017b) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci 114(16):4213–4218. https://doi.org/10.1073/pnas.1613203114
Edwards KT (2017) The role of patient participation in drug approvals: Lessons from the accelerated approval of eteplirsen. Food Drug Law J 72(3):406–450
FDA (2016a) EXONDYS-51 label. FDA, Rome
FDA (2016b) FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. FDA, Rome
FDA (2019) FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation. FDA, Rome
FDA (2020) FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation. FDA, Rome
FDA (2021) FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation. FDA, Rome
Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL, Judge DP, Lal AK, Markham LW, Parks WJ, Tsuda T, Wang PJ, Yoo SJ (2017) Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the American Heart Association. Circulation 136(13):e200–e231. https://doi.org/10.1161/CIR.0000000000000526
Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, Charleston JS, Sardone V, Domingos J, Dickson G, Straub V, Guglieri M, Mercuri E, Servais L, Muntoni F (2020) Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology 94(21):e2270–e2282. https://doi.org/10.1212/WNL.0000000000009233
Gait MJ, Arzumanov AA, McClorey G, Godfrey C, Betts C, Hammond S, Wood MJA (2019) Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment. Nucl Acid Ther 29(1):1–12. https://doi.org/10.1089/nat.2018.0747
Gao X, Zhao J, Han G, Zhang Y, Dong X, Cao L, Wang Q, Moulton HM, Yin HF (2014) Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice. Mol Therapy 22(7):1333–1341. https://doi.org/10.1038/mt.2014.63
Graeff C, Marin F, Petto H, Kayser O, Reisinger A, Peña J, Zysset P, Glüer C-C (2013) High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis. Bone 52(2):568–577. https://doi.org/10.1016/j.bone.2012.10.036
Gumerson JD, Michele DE (2011) The dystrophin-glycoprotein complex in the prevention of muscle damage. J Biomed Biotechnol. https://doi.org/10.1155/2011/210797
Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, Wong M, Smith WB, Vutikullird A, Kaye E (2014) Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: Results of two single-ascending-dose studies. Antimicrob Agents Chemother 58(11):6639–6647. https://doi.org/10.1128/AAC.03442-14
Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen G-JB, van Deutekom JCT, Aartsma-Rus A (2009) In vivo comparison of 2’-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11:257–266. https://doi.org/10.1002/jgm
Heo Y-A (2020) Golodirsen: first approval. Drugs 80(3):329–333. https://doi.org/10.1007/s40265-020-01267-2
Hilhorst N, Spanoudi-Kitrimi I, Goemans N, Morren MA (2018) Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study. Eur J Pediatr. https://doi.org/10.1007/s00431-018-3272-1
Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchene muscular dystrophy locus. Biotechnology 51(6):919–928
Holland A, Gunnoo S, Ching S, Johnson R, Irwin C, Bracegirdle S, Godfrey C (2021) A novel enhanced delivery oligonucleotide (EDO) therapeutic demonstrates considerable potential in treating Duchenne muscular dystrophy
Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD (1996) Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucl Acid Drug Dev 6(4):267–272. https://doi.org/10.1089/oli.1.1996.6.267
Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR (2003) Efficacy of antisense morpholino oligomer targeted to c- myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 9:2510–2519
Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV, Welch LS, Panchal RG, Bavari S (2012) Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 4(11):2806–2830. https://doi.org/10.3390/v4112806
Kaspar R-W, Allen HD, Montanaro F (2013) Curren understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy. J Am Acad Nurse Pract 21(5):241–249. https://doi.org/10.1111/j.1745-7599.2009.00404.x.Current
Kesselheim AS, Avorn J (2016) Approving a problematic muscular dystrophy drug: implications for FDA policy. J Am Med Assoc 316(22):2357–2358. https://doi.org/10.1001/jama.2016.16437
Khan N, Eliopoulos H, Han L, Kinane TB, Lowes LP, Mendell JR, Gordish-Dressman H, Henricson EK, McDonald CM (2019) Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy. J Neuromuscul Dis 6(2):213–225. https://doi.org/10.3233/JND-180351
Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJA, Wells DJ, Wilton SD, Muntoni F (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8(10):918–928. https://doi.org/10.1016/S1474-4422(09)70211-X
Kinane TB, Mayer OH, Duda PW, Lowes LP, Moody SL, Mendell JR (2018) Longterm pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history. J Neuromuscul Dis 5:47–58
Klingler W, Jurkat-rott K, Lehmann-horn F, Schleip R (2012) The role of fibrosis in Duchenne muscular dystrophy. Acta Myologica 31:184–195
Koeks Z, Bladen CL, Salgado D, Van Zwet E, Pogoryelova O, McMacken G, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Bellgard MI, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Lochmüller H (2017) Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database. J Neuromuscul Dis 4(4):293–306. https://doi.org/10.3233/JND-170280
Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Müller CR, Lindlöf M, Kaariainen H, de la Chapelle A, Kiuru A, Savontaus ML, Gilgenkrantz H, Récan D, Chelly J, Kaplan JC, Covone AE, Archidiacono N, Kunkel LM (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45(4):498–506
Korinthenberg R (2019) A new era in the management of Duchenne muscular dystrophy. Dev Med Child Neurol 61(3):292–297. https://doi.org/10.1111/dmcn.14129
Lamb MM, West NA, Ouyang L, Yang M, Weitzenkamp D, James K, Ciafaloni E, Pandya S, Diguiseppi C, Cunniff C, Meaney J, Andrews J, Pettit K, Pettygrove S, Miller L, Matthews D, Montgomery A, Donnelly J, Bolen J, Fox D (2016) Corticosteroid treatment and growth patterns in ambulatory males with Duchenne muscular dystrophy. J Pediatr 173:207-213.e3. https://doi.org/10.1016/j.jpeds.2016.02.067
Le S, Yu M, Hovan L, Zhao Z, Ervasti J, Yan J (2018) Dystrophin As a Molecular Shock Absorber [Research-article]. ACS Nano 12(12):12140–12148. https://doi.org/10.1021/acsnano.8b05721
Lehto T, Alvarez AC, Gauck S, Gait MJ, Coursindel T, Wood MJA, Lebleu B, Boisguerin P (2014) Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucl Acids Res 42(5):3207–3217. https://doi.org/10.1093/nar/gkt1220
Lim KRQ, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Dev Ther 11:533–545. https://doi.org/10.2147/DDDT.S97635
Lim KRQ, Echigoya Y, Nagata T, Kuraoka M, Kobayashi M, Aoki Y, Partridge T, Maruyama R, Takeda S, Yokota T (2019) Efficacy of multi-exon skipping treatment in Duchenne muscular dystrophy dog model neonates. Mol Ther 27(1):76–86. https://doi.org/10.1016/j.ymthe.2018.10.011
McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S, Wilton SD (2006a) Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord 16(9–10):583–590. https://doi.org/10.1016/j.nmd.2006.05.017
McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD (2006b) Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13(19):1373–1381. https://doi.org/10.1038/sj.gt.3302800
McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, Clemens PR, Hoffman EP, Cnaan A, Gordish-Dressman H, Vishwanathan V, Chidambaranathan S, Biggar WD, McAdam LC, Mah JK, Tulinius M, Morgenroth LP, Leshner R, Tesi-Rocha C, Karachunski P (2018) Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 391(10119):451–461. https://doi.org/10.1016/S0140-6736(17)32160-8
Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore M, Kean JR, Allen HD, Shilling C, Melia KR, Kaye EM (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74(5):637–647. https://doi.org/10.1002/ana.23982
Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79(2):257–271. https://doi.org/10.1002/ana.24555
Mendell JR, Sahenk Z, Rodino-Klapac LR (2017) Clinical trials of exon skipping in Duchenne muscular dystrophy. Expert Opin Orphan Drugs 5(9):683–690. https://doi.org/10.1080/21678707.2017.1366310
Mendell JR, Khan N, Sha N, Eliopoulos H, McDonald CM, Goemans N, Mercuri E, Lowes LP, Alfano LN (2021) Comparison of long-term ambulatory function in patients with Duchenne muscular dystrophy treated with eteplirsen and matched natural history controls. J Neuromuscul Dis 1:1–11. https://doi.org/10.3233/JND-200548
Miyatake S, Mizobe Y, Tsoumpra MK, Lim KRQ, Hara Y, Shabanpoor F, Yokota T, Takeda S, Aoki Y (2019) Scavenger receptor class A1 mediates uptake of morpholino antisense oligonucleotide into dystrophic skeletal muscle. Mol Therapy Nucl Acids 14:520–535. https://doi.org/10.1016/j.omtn.2019.01.008
Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L (2013) Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet 21(10):1049–1053. https://doi.org/10.1038/ejhg.2012.301
Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL (2004) Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 15(2):290–299. https://doi.org/10.1021/bc034221g
Muntoni F, Frank DE, Morgan J, Domingos J, Schnell FJ, Dickson G, Popplewell L, Guglieri M, Seferian A, Monforte M, Mercuri E, Servais L, Straub V (2018) Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression in patients with genetic mutations amenable to exon 53 skipping. Neuromuscul Disord 28:S5. https://doi.org/10.1016/s0960-8966(18)30304-3
Nelson MH, Stein DA, Kroeker AD, Hatlevig SA, Iversen PL, Moulton HM (2005) Arginine-rich peptide conjugation to morpholino oligomers: Effects on antisense activity and specificity. Bioconjug Chem 16(4):959–966. https://doi.org/10.1021/bc0501045
Niks EH, Aartsma-Rus A (2017) Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Ther 17(2):225–236. https://doi.org/10.1080/14712598.2017.1271872
Pascual-Morena C, Cavero-Redondo I, Álvarez-Bueno C, Mesas AE, Pozuelo-Carrascosa D, Martínez-Vizcaíno V (2020) Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: a systematic review. Ann Clin Transl Neurol 7(9):1738–1752. https://doi.org/10.1002/acn3.51149
Rahimov F, Kunkel LM (2013) The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. J Cell Biol 201(4):499–510. https://doi.org/10.1083/jcb.201212142
Sarepta Therapeutics (2021) Clinical update: results from 30 mg / kg cohort of momentum study of srp-5051 for Duchenne muscular dystrophy. Sarepta Therapeutics, Cambridge
Sazani P, Weller DL, Shrewsbury SB (2010) Safety pharmacology and genotoxicity evaluation of AVI-4658. Int J Toxicol 29(2):143–156. https://doi.org/10.1177/1091581809359206
Sazani P, Ness KPV, Weller DL, Poage DW, Palyada K, Shrewsbury SB (2011) Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of Duchenne muscular dystrophy. Int J Toxicol 30(3):313–321. https://doi.org/10.1177/1091581811403505
Shimatsu Y, Yoshimura M, Yuasa K, Urasawa N, Tomohiro M, Nakura M, Tanigawa M, Nakamura A, Takeda S (2005) Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol 24(2):145–154
Shirley M (2021) Casimersen: first approval. Drugs 81(7):875–879. https://doi.org/10.1007/s40265-021-01512-2
Spurney C, Shimizu R, Morgenroth LP, Kolski H, Gordish-Dressman H, Clemens PR, Cregan M, Goude E, Glick M, Johnson L, Han J, Joyce N, Kilmer D, Nicorici A, Chidambaranathan C, Kumar S, Eliasoph L, Hosaki E, Gonzales A, Zimmerman A (2014) Cooperative international neuromuscular research group Duchenne natural history study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 50(2):250–256. https://doi.org/10.1002/mus.24163
Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucl Acid Drug Dev 7(3):187–195. https://doi.org/10.1089/oli.1.1997.7.187
Takizawa H, Takeshita E, Sato M, Shimizu-Motohashi Y, Ishiyama A, Mori-Yoshimura M, Takahashi Y, Komaki H, Aoki Y (2021) Highly sensitive screening of antisense sequences for different types of DMD mutations in patients’ urine-derived cells. J Neurol Sci 423:117337. https://doi.org/10.1016/j.jns.2021.117337
Thomas SS, Buckon CE, Nicorici A, Bagley A, Mcdonald CM, Sussman MD (2013) Classification of the gait patterns of boys with Duchenne muscular dystrophy and their relationship to function. J Child Neurol 25(9):1103–1109. https://doi.org/10.1177/0883073810371002.Classification
Tsoumpra MK, Fukumoto S, Matsumoto T, Takeda S, Wood MJA, Aoki Y (2019) Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. EBioMedicine 45:630–645. https://doi.org/10.1016/j.ebiom.2019.06.036
Wagner KR, Kuntz NL, Koenig E, East L, Upadhyay S, Han B, Shieh PB (2021) Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. https://doi.org/10.1002/mus.27347
Warren TK, Ph D, Saoud JB, Ph D, Ibrahim MA, Ch B, Wells J, Warfield KL, Ph D, Swenson DL, Ph D, Welch LS, Sazani P, Ph D, Wong M, Berry D, Ph D, Kaye EM, Bavari S, Ph D (2015) AVI-7288 for Marburg virus in nonhuman primates and humans. N Engl J Med 373(4):339–348. https://doi.org/10.1056/NEJMoa1410345
Worton RG (1992) Duchenne muscular dystrophy: gene and gene product; mechanism of mutation in the gene. J Inherit Metab Dis 15(4):539–550. https://doi.org/10.1007/BF01799613
Wu RP, Youngblood DS, Hassinger JN, Lovejoy CE, Nelson MH, Iversen PL, Moulton HM (2007) Cell-penetrating peptides as transporters for morpholino oligomers: Effects of amino acid composition on intracellular delivery and cytotoxicity. Nucl Acids Res 35(15):5182–5191. https://doi.org/10.1093/nar/gkm478
Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P, Wood MJA (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17(24):3909–3918. https://doi.org/10.1093/hmg/ddn293
Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL, Wood MJA (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18(22):4405–4414. https://doi.org/10.1093/hmg/ddp395
Yin H, Moulton HM, Betts C, Merritt T, Seow Y, Ashraf S, Wang Q, Boutilier J, Wood MJA (2010) Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther 18(10):1822–1829. https://doi.org/10.1038/mt.2010.151
Yin H, Boisguerin P, Moulton HM, Betts C, Seow Y, Boutilier J, Wang Q, Lebleu B, Wood MJA (2013) Context dependent effects of chimeric peptide morpholino conjugates contribute to dystrophin exon-skipping efficiency. Mol Ther 2:1–10. https://doi.org/10.1038/mtna.2013.51
Zingariello CD, Kang PB (2018) Dollars and antisense for Duchenne muscular dystrophy. Neurology 90(24):1091–1092. https://doi.org/10.1212/WNL.0000000000005669
Funding
This work was supported by Muscular Dystrophy Canada, the Friends of Garrett Cumming Research Fund, the HM Toupin Neurological Science Research Fund, Fulbright Scholarship Program, and the Women and Children’s Health Research Institute (WCHRI).
Author information
Authors and Affiliations
Contributions
Literature review draft preparation by OS. Supervision and funding acquisition by TY. Review and editing performed jointly. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
TY is a founder and shareholder of OligomicsTx, which aims to commercialize antisense oligonucleotide technology. OS has no conflicts of interest to report.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent to publish
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sheikh, O., Yokota, T. Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update. Arch Toxicol 96, 1–9 (2022). https://doi.org/10.1007/s00204-021-03184-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-021-03184-z